Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarperprumig in ANCA-associated vasculitis (Phase II, randomized, double-blind, placebo-controlled)
CTR20260199Phase 2Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tarperprumig in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), sponsored by Alexion Pharmaceuticals. Started Apr 2026; status: active.
02
Drugs
tarperprumig
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on CTR20260199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260199.